AAA appoints two additional Board Members

AAA Board appointed two new members, Claudio Costamagna and Andrea Ruben Levi. The newly appointed Board members are well-known representative of the business and scientific community.

Claudio Costamagna is founder and chairman of the financial advisory boutique CC&Co and independent Board member of outstanding Italian and international groups such as Luxottica Group, Bulgari SpA, Autogrill SpA, and DEA Capital SpA. He previously covered major roles in Goldman sachs which he left in May 2006 after 18 years. He was Chairman of the Investment Banking division for Europe, the Middle East and Africa and prior to this position, co-Head of the Investment Banking Division for Goldman Sachs International in Europe, co-Head of the bank’s Investment Banking Services in Europe, Head of the Italian team for the Investment Banking Division in London, and Chairman of Goldman Sachs SIM as well as member of the firm’s partnership and European Management Committee.

Andrea Ruben levi is President, CEO and principal shareholder of Parabensa and Delpa, the holding and administrative companies of an international group developing, designing and producing engine parts for cars. The Group holds companies in Italy, India and Poland. Prior to this, Mr. Levi earned a Ph.D. in Physics from MIT, and he spent several years doing research on nuclear physics, biophysics, and computional physics in Boston, Massachusetts, United States.

The Board of Directors now consists of 9 persons, 4 are from AAA Management, and 5 are non-executive Directors.

AAA announces the production and commercialisation of a new radiopharmaceutical in France

Thanks to a licensing agreement with IASON GmbH, an Austrian-based company specialized in the production of nuclear medicine radiopharmaceuticals, AAA is now allowed to produce and sell IASOFLU in France. IASOFLU is a new 18F sodium fluoride pharmaceutical used to detect and stage skeletal metastasis, a highly common disease in patients suffering from breast and prostate cancer. IASOFLU is produced at the French site in Troyes and is benefiting from the support of the site’s R&D and production teams. The first doses have been delivered to Creil and Tenon hospitals.

AAA awarded by Deloitte Fast Technology 50 as the fastest growing technology company in Rhône-Alpes Auvergne Region

AAA was awarded the first prize of the ninth edition of the Rhône-Alpes Auvergne Deloitte Technology Fast 50, one of the foremost technology award programs which is a ranking of the country’s 50 fastest-growing technology companies based on percentage growth over five years. The Fast 50 program recognizes the achievements, growth and contributions of the fastest-growing technology at a regional and national level.

Citing AAA 5-year revenue growth of over 1,826% (from € 600,000 to € 11.58M), AAA was honored and excited to have its impressive revenue growth be acknowledged by Deloitte, and believe it speaks to the continued committment to translate the outstanding academic research that characterize Molecular Medecine into commercial products. AAA success has mainly been driven by the production and commercialisation of its FDG Pet tracer Gluscan® and by the acquisition and development of GiPharma.

Mr Stefano Buono – AAA President and CEO – and Mr Heinz Mauesli, CFO, received the prize today in Lyon.

AAA to support University of Lausanne Hospitals

The University of Lausanne Hospitals (CHUV) will participate in a study on the impact of F-18 Fluorocholine PET/CT and MR Imaging/Spectroscopy in the Management of primary and recurrent prostate cancer. The sponsors and collaborators of this study are AAA and the Centre d’Imagerie Biomédicale (CIBM) in Lausanne. This study will run in parallel to the work-up of primary prostate cancer, as the F-Choline radiopharmaceutical will be available during the time of study at absolutely no cost to patients or CHUV. A number of studies have demonstrated the benefits of F-18 FCH PET/CT for these patients and this indication is currently not reimbursed by the Swiss obligatory health insurance providers.

GiPharma acquires a new licence in France

Gipharma was recently granted marketing authorization in France for Mibitec, a generic version of the widest used SPECT cardiac imaging agent. Mibitec has approved indications for Myocardial perfusion scintigraphy, detection and localization of coronary artery disease and myocardial infarction, assessment of global ventricular function, detection of suspected breast cancer, and localization of hyper-functioning parathyroid tissue.

AAA enters SNM Clinical Trials Network

Advanced Accelerator Applications, Erigal Limited and IBA Molecular – all European suppliers of radiopharmaceuticals used in PET imaging – have signed up to the SNM Clinical Trials Network, which currently has 201 affiliated PET manufacturing sites globally. The network is an initiative designed to address the need for streamlined drug discovery through the integration of imaging biomarkers into multicenter clinical trials. It also gained investigational new drug status for using fluorothymidine in its multicenter trials.

AAA strengthens the collaborations with Université de la Méditerranée

June 25th, 2009 – AAA signed today a new collaboration agreement with the Marseille-based Université de la Mediterranée after winning the tender for the construction of a production and R&D laboratory in 2008. According to the agreement, AAA will act as a private company hosted in the CERIMED – European Centre for Research in Medical Imaging – premises for the production and sale of radiotracers in France and abroad. AAA will also become one of CERIMED’s privileged partners for the research and development of new radiopharmaceuticals, as well as for the commercial exploitation. The construction of the production and R&D site, which will host three radiopharmaceutical laboratories and two cyclotrons, should start in October 2010, and should be operational and ready for sales at the end of 2011. Headquartered in Marseille, CERIMED is a project aiming at a European centre of excellence for the development of molecular imaging technologies to promote a multidisciplinary community working in the field of medical imaging.

Maurizio Mariani is the new Head of R&D

April 2nd, 2009 – AAA announces today that Dr. Maurizio Mariani joined the group as the new Head of R&D. Prior to joining AAA, Dr. Maurizio Mariani held the position of General Manager of Merck Serono RBM S.p.A. (Colleretto Giacosa, Italy) and of Head Exploratory Medicine for the Merck Serono Group (Geneva, Switzerland). Dr. Mariani holds a degree in Medicine and Surgery from La Sapienza University, Rome, Italy and a PhD in Pharmacology from Temple University, Philadelphia, United States. In 1991 he obtained the Diploma of the American Board of Toxicology (DABT). Dr. Mariani has a long experience in pharmaceutical research and development.

AAA to manage THERANEAN project with Lyonbiopôle

March 26th, 2009 – Following the 7th Call for Projects of the Single Inter-Ministry Fund (FUI) in 2008, Lyonbiopôle obtained funding for four new R&D projects from various companies, including the THERANEAN (THERApy through NEutron Activation using Nanoparticles) R&D project. The objective of the THERANEAN project is the development and pre-clinical validation of a methodology for solid tumors therapy. This methodology is based on the use of sub-micrometric/nano particles charged with beta/gamma emitters produced in a cyclotron-driven neutron activator. AAA is the project leader together with CERMA, Centre d’Etude et de Recherche Médicale d’Archamps, and other universities and research centers.

AAA Italy gets the authorizations to handle transportations

AAA Italy obtained all the necessary authorizations to transport by road radioactive materials in Italy. The company will achieve approximately a € 60 cost saving for every transport, as it will no longer have to pay a commission to other companies for the use of their transport authorization. The annual costs savings will be well beyond €100,000.